As MET pathway activation is considered a bona fide bypass resistance pathway in human EGFR-driven lung cancers, murine oncogene-driven lung tumors propagated in immune-competent hosts may represent tractable model systems to explore acquired drug resistance and to define novel combination therapy strategies for prolonging progression free survival. This evidence concerns the gene MET and lung cancer.